CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma. The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial for patients with targeting Glypican-3 positive to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma and R/R PCL, as well as KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. It has collaborated with Moderna, Inc. to investigate satricabtagene autoleucel in combination with Moderna's investigational Claudin18.2 mRNA product.; and East China University of Science and Technology (ECUST) to leverage synergies between academic and industrial resources. The company was founded in 2014 and is headquartered in Shanghai, China.